Allergan delivered good results in the third quarter, in spite of the strong U.S. dollar relative to virtually all major currencies. The U.S.-based company reported product sales of $1,391.1 million for the quarter ended Sept. 30, representing a 6.1 percent increase over the same period a year earlier, or 9.4 ...

Buying a membership today will give you:
To continue reading this article register now.